SecBot SecBot
Biotech Drug Report Generated Jul 1, 2026

MR-141 (phentolamine ophthalmic solution 0.75%)

VTRS·Viatris Inc
NEUTRAL
Drug Impact Rating5/10
Trial phase
Filed/sNDA under FDA review (Phase 3 completed)
Time to market
If approved at the October 17, 2026 PDUFA date, commercial launch could follow within weeks (Ryzumvi is already manufactured and marketed for its approved indication).
Why 5/10
Next hard, dated catalyst is the PDUFA goal date of October 17, 2026 (~3.5 months away) for FDA decision on the supplemental NDA seeking to expand Ryzumvi's label to include presbyopia. This is a sNDA for an already-approved drug (Ryzumvi was approved Sept 2023 for reversing pupil dilation), so the binary risk is moderate. However, Viatris is a $14.3B-revenue diversified pharma (market cap ~$18-19B), so this label expansion, while meaningful, is not a make-or-break value driver for the stock.
Actionable Insight NEUTRAL

Watch for the October 17, 2026 PDUFA decision on MR-141's presbyopia label expansion. Approval would add a differentiated non-pilocarpine presbyopia drop to Viatris's portfolio but faces crowded competition (Vuity, Qlosi, newly-approved Yuvezzi). For VTRS, this is a single positive catalyst in a broader turnaround story, not a stock-defining binary. The stock already rallied ~11% in 5 days on the sNDA acceptance news in Feb 2026.

Price Chart

Loading chart...

Executive Summary

MR-141 is the same phentolamine ophthalmic solution 0.75% already marketed as Ryzumvi (FDA-approved September 2023 to reverse pharmacologically-induced pupil dilation after eye exams). Viatris is now seeking a label expansion to treat presbyopia, a large and growing market (~128 million Americans affected). Two positive Phase 3 trials support the application, with a PDUFA decision date of October 17, 2026. The drug has a differentiated mechanism (alpha-blocker) vs. existing presbyopia drops (which are mostly cholinergic agonists like pilocarpine). However, the presbyopia eye drop market is becoming crowded with competitors including Vuity (AbbVie/Allergan), Qlosi (Orasis), and newly-approved Yuvezzi (Tenpoint Therapeutics). For Viatris (a $14.3B-revenue global pharma company), this is a meaningful pipeline asset but represents a modest portion of total company value.

How It Works

Phentolamine is a non-selective alpha-1 and alpha-2 adrenergic antagonist, it blocks certain receptors in the iris dilator muscle, causing the pupil to constrict. This creates a "pinhole" effect that sharpens near vision, helping people with presbyopia (age-related inability to focus on close objects) see up close without reading glasses. It is a once-daily eye drop used in the evening.

Trial Status

Two pivotal Phase 3 trials (VEGA-2 and VEGA-3) completed. VEGA-3 (NCT06542497) enrolled 545 patients randomized 3:2 to MR-141 or placebo once daily in the evening. Positive top-line results announced June 26, 2025, met primary endpoint (≥3-line gain in binocular near visual acuity at 12 hours post-dose on day 8 and at 1 hour post-dose on day 1) and all secondary endpoints without compromising distance vision. sNDA accepted by FDA February 25, 2026. PDUFA goal date October 17, 2026.

The Two-Sided Case

▲ Bull Case5
Differentiated mechanism, phentolamine is an alpha-blocker that constricts the pupil via the iris dilator muscle, distinct from pilocarpine-based competitors (Vuity, Qlosi) that act on the sphincter muscle, potentially offering a different side-effect profile with less brow ache/dim vision.
Both pivotal Phase 3 trials (VEGA-2 and VEGA-3) met primary and all secondary endpoints, showing statistically significant improvement in near vision without compromising distance vision or causing serious treatment-related adverse events.
PDUFA date of October 17, 2026 is imminent (~3.5 months away), and as a sNDA for an already-approved drug with established safety, the probability of approval is reasonably high.
Presbyopia market is large and growing, ~128 million Americans affected, with the presbyopia eye drops market valued at ~$2.8B in 2025 and expected to grow at 7.6% CAGR to $5.1B by 2033. Viatris has an existing ophthalmic commercialization infrastructure for Ryzumvi.
Viatris analyst consensus is favorable, 12 buy/strong buy ratings vs. 5 hold and 1 sell, with a mean price target of $17.81 (18.2% implied upside from ~$15.88).
▼ Bear Case5
Crowded competitive landscape, Vuity (AbbVie/Allergan) is the established market leader since 2021, Qlosi (Orasis) launched April 2025, and Yuvezzi (Tenpoint Therapeutics) was just FDA-approved in January 2026 as the first dual-agent presbyopia drop. MR-141 would be entering a market with multiple entrenched and new competitors.
Viatris is a large, diversified pharma company ($14.3B revenue, ~$18-19B market cap). Even a successful presbyopia launch would be incremental, unlikely to move the stock more than a few percent. The drug is not a make-or-break value driver.
Ryzumvi's current approved indication (reversing pupil dilation) is a niche market with modest sales, so there is no large existing revenue base to leverage. The presbyopia opportunity requires a new commercial build-out in an increasingly competitive space.
Phentolamine is an older drug (original FDA approval dates to 1952 as an injectable), so patent protection may be limited, and the sNDA relies on the 505(b)(2) pathway, which could face future generic competition sooner than a novel entity.
Recent insider activity shows a CFO sold ~$810K worth of shares under a 10b5-1 plan in June 2026, and Q1 2026 EPS estimates were revised down 7 times in the last 90 days for the upcoming quarter.

Upcoming Catalysts

  • October 17, 2026, PDUFA goal date for FDA decision on MR-141 sNDA for presbyopia
  • Potential FDA Advisory Committee meeting (if convened) ahead of the PDUFA date
  • Q2 and Q3 2026 earnings reports for Viatris (broader company context)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Viatris Inc 8-K VTRS ·Originating report

Sources · 13

Hover a chip for the title
1 newsroom.viatris.com2 newsroom.viatris.com3 glance.eyesoneyecare.com4 newsroom.viatris.com5 ophthalmologybreakingnews.com6 ophthalmologyadvisor.com7 drugs.com8 businesswire.com9 orasis-pharma.com10 dataintelo.com11 newsroom.viatris.com12 sec.gov13 prnewswire.com